Skip to main content
. Author manuscript; available in PMC: 2016 Aug 17.
Published in final edited form as: Ann Thorac Surg. 2016 Jan 20;101(6):2407–2416. doi: 10.1016/j.athoracsur.2015.12.004

Table 2.

Gene Therapy Clinical Trials for Heart Failure

Therapeutic Target Transgene Route Vector Number of Patients Phase Procedure Status Results End Points Follow-Up Reference/Identifier
Heart failure SERCA2a intracoronary AAV1     9 1,2 primary treatment completed positive safety, walk test, angina class 1 year [45]
Heart failure SERCA2a intracoronary AAV1   39    2 primary treatment completed positive walk test, hospitalizations, angina class 3 years [46] NCT00454818
Heart failure SERCA2a intracoronary AAV1 250  2b primary treatment completed N/A time to recurrent event 1 year [47] NCT01643330
Heart failure SERCA2a intracoronary AAV1   24 1,2 LVAD enrolling N/A safety, walk test, angina class N/A NCT00534703
Heart failure AC6 intracoronary adenovirus   72 1,2 primary treatment enrolling N/A treadmill test, ECHO N/A [48] NCT00787059
Heart failure SDF-1 intramyocardial plasmid   93    2 primary treatment completed no effect walk test, angina class 4 mo [49] NCT01643590

AAV = adeno-associated virus; AC6 = adenylyl cyclase type 6; ECHO = echocardiography; LVAD = left ventricular assist device; N/A = not available; NCT = clinicaltrals.gov.identifier; SDF-1 = stromal-derived factor 1; SERCA2a = sarcoplasmic reticulum adenosine triphosphatase isoform 2a.